In a strategic collaboration with Novartis, Axiologo has embarked on an ambitious project known as the Stability Modeller. This initiative focuses on enhancing the predictability of drug stability, a critical factor in the pharmaceutical industry that encompasses both physical (crystallization, state change, etc.) and chemical (impurities, degradation, etc.) aspects. The project’s goal is to develop predictive models that can forecast the outcomes of long-term stability tests based on short-term stress testing data, thereby streamlining the R&D process and facilitating the quicker introduction of stable, market-ready pharmaceutical products.
Key Goals:
Technologies Deployed:
The Stability Modeller project has underscored the paramount importance of stability in the development and registration of new generic drugs. With the predictive capabilities now in place, Novartis is better equipped to make informed decisions throughout the drug development process, significantly increasing the likelihood of market success. The profound impact of this project lies in its contribution to ensuring that new pharmaceuticals are not only effective but also stable, safe, and quickly brought to market. Although quantifying the exact impact on market success rates can be challenging, the implications for operational efficiency and product quality are clear and substantial.
As Axiologo continues to refine and expand upon the capabilities introduced by the Stability Modeller, the future of pharmaceutical R&D looks increasingly promising, with AI-driven innovations paving the way for faster, more reliable drug development cycles.
